June 1, 2015.
The American Society of Clinical Oncology (ASCO) will run a trial of its enrolling patients with advanced cancers but a dearth of standard treatment options. The trial will offer molecularly-targeted cancer drugs contributed free of charge by participating pharma companies.
The Targeted Agent and Profiling Utilization Registry (TAPUR) study will give “real-world” data on best uses of these drugs outside of approved indications.
ASCO petitioned several companies to sign on. Five major companies, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, and Pfizer, so far, have agreed to participate by signing memoranda of understanding.
See the press release here.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.